April 08, 2024 11:36 AM Eastern Daylight Time
BUSINESS WIRE
Riassunto: Lo studio clinico comparativo di fase 3 condotto sul candidato biosimilare Prolia ® e Xgeva ® (denosumab) HLX14 soddisfa gli endpoint primari
Tweet
View Full Size
Download
Full Size
JPEG
,
2100
x
315
,
180.7 KB
Small
JPEG
,
480
x
72
,
31.3 KB
Preview
JPEG
,
144
x
22
,
7.2 KB
Thumbnail
JPEG
,
120
x
18
,
4.8 KB
Smart Multimedia Gallery
View and Share Logo
Download Full Size
Download Small
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Riassunto: Lo studio clinico comparativo di fas...